Enanta Pharmaceuticals (ENTA) Receiving Somewhat Positive Press Coverage, Report Finds

Headlines about Enanta Pharmaceuticals (NASDAQ:ENTA) have been trending somewhat positive recently, according to Accern Sentiment Analysis. Accern identifies negative and positive press coverage by monitoring more than 20 million blog and news sources in real time. Accern ranks coverage of companies on a scale of negative one to one, with scores nearest to one being the most favorable. Enanta Pharmaceuticals earned a daily sentiment score of 0.13 on Accern’s scale. Accern also gave media headlines about the biotechnology company an impact score of 46.4040511760257 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the company’s share price in the immediate future.

Enanta Pharmaceuticals (NASDAQ ENTA) opened at $59.20 on Wednesday. The company has a market capitalization of $1,130.00, a price-to-earnings ratio of 74.00 and a beta of 0.64. Enanta Pharmaceuticals has a twelve month low of $25.92 and a twelve month high of $59.34.

Enanta Pharmaceuticals (NASDAQ:ENTA) last issued its quarterly earnings data on Monday, November 20th. The biotechnology company reported $1.86 earnings per share (EPS) for the quarter, missing the consensus estimate of $2.13 by ($0.27). The firm had revenue of $75.93 million for the quarter, compared to analysts’ expectations of $73.80 million. Enanta Pharmaceuticals had a return on equity of 6.46% and a net margin of 17.23%. The business’s revenue for the quarter was up 491.3% compared to the same quarter last year. During the same period in the previous year, the business posted ($0.09) EPS. analysts anticipate that Enanta Pharmaceuticals will post -1.57 earnings per share for the current fiscal year.

ENTA has been the topic of several recent analyst reports. TheStreet raised Enanta Pharmaceuticals from a “c+” rating to a “b-” rating in a report on Wednesday, December 13th. Zacks Investment Research raised Enanta Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Tuesday, October 10th. Royal Bank of Canada increased their target price on Enanta Pharmaceuticals from $54.00 to $58.00 and gave the company an “outperform” rating in a report on Tuesday, November 21st. Finally, JMP Securities increased their target price on Enanta Pharmaceuticals from $40.00 to $53.00 in a report on Wednesday, October 4th. Three research analysts have rated the stock with a hold rating and four have issued a buy rating to the stock. Enanta Pharmaceuticals currently has an average rating of “Buy” and a consensus price target of $46.25.

COPYRIGHT VIOLATION NOTICE: This report was posted by Community Financial News and is the sole property of of Community Financial News. If you are viewing this report on another site, it was illegally stolen and republished in violation of U.S. & international copyright laws. The original version of this report can be read at https://www.com-unik.info/2017/12/27/enanta-pharmaceuticals-enta-receiving-somewhat-positive-press-coverage-report-finds.html.

Enanta Pharmaceuticals Company Profile

Enanta Pharmaceuticals, Inc is a research and development-focused biotechnology company. The Company uses chemistry-driven approach and drug discovery solutions to create small molecule drugs for the treatment of viral infections and liver diseases. Its research and development programs are focused on three disease targets: non-alcoholic steatohepatitis (NASH)/ primary biliary cholangitis (PBC), respiratory syncytial virus (RSV) and hepatitis B virus (HBV).

Insider Buying and Selling by Quarter for Enanta Pharmaceuticals (NASDAQ:ENTA)

What are top analysts saying about Enanta Pharmaceuticals? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Enanta Pharmaceuticals and related companies.


Leave a Reply

share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit